Home > Insider Trading > Filing (0001209191-16-137314)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1377121	Protagonist Therapeutics Inc	PTGX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1552293	Edward S. Torres	C/O Lilly Ventures 115 West Washington St., Ste.1680-South Indianapolis IN 46204	No	No	Yes	No
1575852	Lilly Ventures Fund I Llc	115 West Washington Street Suite 1680-South Indianapolis IN 46204	No	No	Yes	No
1602732	Edward Steven Hall	C/O Lilly Ventures 115 West Washington St., Ste. 1680-South Indianapolis IN 46204	No	No	Yes	No
1681884	Lv Management Group, Llc	115 West Wahington Street Suite 1680-South Indianapolis IN 46204	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-08-16	206,896	$0.00	206,896	No	4	C	Indirect	By Fund
Common Stock	Acquisiton	2016-08-16	630,541	$0.00	837,437	No	4	C	Indirect	By Fund
Common Stock	Acquisiton	2016-08-16	678,712	$0.00	1,516,149	No	4	C	Indirect	By Fund
Common Stock	Acquisiton	2016-08-16	583,333	$12.00	2,099,482	No	4	P	Indirect	By Fund

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Fund
No	4	C	Indirect	By Fund
No	4	C	Indirect	By Fund
No	4	P	Indirect	By Fund

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2016-08-16	3,000,000	$0.00	206,896	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-08-16	9,142,857	$0.00	630,541	$0.00
Common Stock	Series C Preferred Stock	Disposition	2016-08-16	9,841,333	$0.00	678,712	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock automatically converted into the Issuer's common stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date.
These shares are held directly by Lilly Ventures Fund I, LLC (LVFI). LV Management Group, LLC (LVMG) is the management company for LVFI and has voting and dispositive power over the shares held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's management committee, which consists of Ed Torres, Steve Hall and Armen Shanafelt. Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of his or its respective proportionate pecuniary interest therein. Dr. Shanafelt is a director of the Issuer and, accordingly, files separate Section 16 reports.